Altimmune Names Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Lead Clinical Development of Pemvidutide
New Appointment: Altimmune, Inc. has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer, effective October 1, 2025, to lead the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH).
Dr. Arbet-Engels' Background: With over 30 years of experience in clinical development and regulatory approvals, Dr. Arbet-Engels previously served as Chief Medical Officer at X4 Pharmaceuticals and has held senior roles at various biopharmaceutical companies, contributing to multiple successful product launches.
Trade with 70% Backtested Accuracy
Analyst Views on XFOR
About XFOR
About the author
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
- Acquisition Deal: Sanofi's agreement to acquire Dynavax for $15.50 per share, totaling approximately $2.2 billion, is expected to enhance its market presence in adult immunization, potentially driving future revenue growth.
- Stock Price Reaction: Following the acquisition announcement, Dynavax shares surged 38.6% to $15.44, indicating a positive market response that may attract further investor interest in the company.
- FDA Approval Impact: Omeros Corp's stock jumped 66.8% to $14.60 after the FDA approved YARTEMLEA for treating related conditions, reflecting strong market demand and optimistic expectations for potential revenues from new drugs.
- Market Dynamics: Companies like Edgewise Therapeutics and Agios Pharmaceuticals also saw significant stock price increases due to positive clinical trial results and FDA approvals, indicating a resurgence of activity and investor confidence in the biotech sector.
Examining X4 Pharmaceuticals' Story Following Leadership Transitions and Recent Funding
Analyst Price Target Adjustments: X4 Pharmaceuticals' consensus analyst price target has decreased from $8.70 to $7.38 due to updated financing scenarios and changes in leadership, reflecting a more cautious outlook on expected returns.
Bullish and Bearish Perspectives: While Stifel maintains a Buy rating despite lowering its price target, indicating confidence in the company's long-term prospects, there are concerns about valuation and the impact of recent recapitalizations on shareholders.
Capital Raise and Strategic Restructuring: The company raised $135 million through a follow-on equity offering and announced a workforce reduction of about 50% to focus on key development initiatives, aiming for significant cost savings.
Financial Metrics Overview: Key financial metrics have been adjusted, with revenue growth expectations lowered and net profit margins increased, suggesting improved profitability despite slower sales expansion.
